Loading stock data…
Halozyme Therapeutics, Inc. (HALO)
$81.93+1.09 (+1.35%)
Market ClosedLast close Jul 24
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Halozyme Therapeutics, Inc. in the Healthcare sector is trading at $81.93 with a market capitalization of $8.3B. Wall Street consensus targets $86.89 (9 analysts), implying a +6.1% move over the next 12 months. The stock is currently near its 52-week high of $82.99, remaining 18.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $376.71M↓ | $451.77M↑ | $354.26M↑ | $325.72M↑ | $264.86M |
| Gross Profit | $297.47M↓ | $373.00M↑ | $299.02M↑ | $279.36M↑ | $216.46M |
| Operating Income | $184.52M↓ | $240.70M↑ | $217.92M↑ | $202.44M↑ | $141.53M |
| Net Income | $150.05M↑ | -$141.59M↓ | $175.22M↑ | $165.16M↑ | $118.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the pate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
158.83%
Volume
Today's trading volume
1.62M
Recent News
Four Stocks Hit New Highs Amid Tech Meltdown
Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris International and KeyCorp are also at highs.
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?
Halozyme Therapeutics recently entered a global partnership and licence agreement with Incyte to apply its Enhanze drug delivery technology to additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms. This collaboration highlights how Halozyme can plug its Enhanze platform into emerging precision oncology assets, potentially broadening future royalty-bearing indications in blood cancers. We’ll now examine how this...
Halozyme and Incyte sign licence agreement for INCA033989 formulations
The companies aim to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development
Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.